The Market Impact of COVID-19 on the Pharma Industry

An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how industry fundamentals and growth prospects have been affected. What can the industry expect going forward?

The COVID-19 pandemic has had an impact on the broader economy and all industries, including the pharmaceutical industry, but how has clinical development, product launches, and overall performance been affected and what can the industry expect going forward? To address those very important questions, the Drug, Chemical & Associated Technologies Association (DCAT) is presenting a webinar, “Pipelines, Product Launches, and Performance: The Market Impact of COVID-19 on the Pharma Industry,” on Tuesday, October 27, from 11:00 AM to 12:30 PM ET, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA.

Graham Headshot

Graham Lewis
Vice President
Global Pharma Strategy
IQVIA

Mr. Lewis is a well-recognized industry expert and widely sought after for his strategic insights for conferences and executive briefings throughout the world, including as a featured speaker at past DCAT Week education programs. The webinar will be moderated by Jim Miller, Content Advisor/Consultant, DCAT, and a preeminent expert in bio/pharmaceutical outsourcing and industry consultant with more than 20 years of experience in the bio/pharmaceutical industry.

As the COVID-19 pandemic remains a major global concern, pharmaceutical companies and their suppliers continue to adjust their operations, including with respect to supply planning, clinical trials, product launches, and the sales impact from new models of customer engagement from physicians and patients. In such a challenging and uncertain environment, pharmaceutical companies and their suppliers must keep fully informed on rapidly changing market conditions and the key trends impacting industry performance. Demand for products and how they are sourced and sold is changing constantly, as is the ability to conduct clinical trials, so industry executives must be fully informed in order to respond quickly and appropriately in this unprecedented market environment.

This 90-minute interactive webinar will provide up-to-the-minute market data and analysis on the current state and medium-term outlook of the global pharmaceutical industry. It will delve deeply into these crucial questions: (1) how have industry fundamentals been impacted in terms of growth prospects and product development; (2) what is the impact and projections for new product launches and the industry’s pipeline; and (3) what may be the “new normal” for the pharma industry, and what can the industry expect going forward?

Further information, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO & Suppliers’ Report: The Rising Strength of Tides

By
Double-digit growth is projected for the markets for peptide and oligonucleotide synthesis, creating opportunities for CDMOs/CMOs.

The Financial Squeeze on Emerging Pharma and Early-Stage Innovation

By
Access to public or private funding remains an existential challenge to fuel early-stage innovation as the biotech industry seeks to recover from a constrained financial & deal-making environment.

Small-Molecule Drugs: Top 10 Market, Sourcing, and Supply-Chain Trends

By
What are key trends and issues that are on the industry’s radar for small-molecule drugs? DCAT Value Chain Insights examines market share, growth rates, product innovation, and API supply chains.

FDA’s Draft Guidance on Platform Technology Designation: The Mfg Impact

By
The FDA has issued much-awaited draft guidance that details how it plans to implement its new platform technology designation program. What does it mean for manufacturing overall and in specific sectors—biologics and advanced therapies?